Clinical Trial Page
Clinical Trial Results:
A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metastatic renal cell cancer (Bevacizumab with standard therapy in RCC)
| Summary | |
EudraCT number | 2005-006161-13 |
Trial protocol | DE |
Global completion date | 28 Jan 2010 |
| Paediatric regulatory details | |
Is the trial part of an agreed EMA paediatric investigation plan? | No |
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | No |
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | No |
| Results information | |
Results version number | v1(current) |
This version publication date | 31 Jan 2016 |
First version publication date | 31 Jan 2016 |
Other versions | |
Summary report(s) | CTg Receipt ML19983 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.